Romidepsin in Conditioning and Maintenance Mitigates Relapse Risk and Enhances NK-Cell Cytotoxicity in Patients Receiving Allogeneic Stem Cell Transplant for Aggressive T-Cell Malignancies: Results of a Phase I/II Clinical Trial
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Chitra Hosing, Zachary Braunstein, Alaa M Ali, Benigno C. Valdez, Borje S. Andersson, Uday R. Popat, Sumithira Vasu, Karilyn Larkin, Sam Penza, Hannah Choe, Ayman Saad, Marcos J.G. de Lima, Lai Wei, Eric McLaughlin, Robin Nakkula, Amanda Campbell, Prashant Trikha, Marcin Puto, Basem M. William, Richard E. Champlin, Dean Anthony Lee, Jonathan E Brammer
Institutions: The University of Texas MD Anderson Cancer Center, The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Ohio State University Hospital, Nationwide Children's Hospital, Abigail Wexner Research Institute, OhioHealth
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200011826